Chronic intravascular coagulation in liver cirrhosis predicts a high hemorrhagic risk

M F Ruberto1, M S Piras, O Sorbello

  • 1Hemostasis and Thrombosis Unit, Department of Medical Science and Public Health, University of Cagliari, Cagliari, Italy. rubertofilomena@tiscali.it.

Insights

Liver cirrhosis involves a hypercoagulable state with increased D-dimer and decreased fibrinogen/platelets, indicating increased hemorrhagic risk due to low-grade intravascular coagulation.

Area of Science:

  • Hepatology
  • Hematology
  • Coagulation Disorders

Background:

  • Liver cirrhosis presents a complex coagulopathy.
  • The underlying mechanism may involve chronic consumption coagulopathy.

Purpose of the Study:

  • To investigate if chronic consumption coagulopathy underlies the coagulopathy in liver cirrhosis.
  • To assess the relationship between coagulation parameters and hemorrhagic risk.

Main Methods:

  • Measured endogenous thrombin generation (ETP ratio) and D-dimer in 282 cirrhotic patients.
  • Analyzed fibrinogen, platelet count, and hemorrhagic score.
  • Compared ETP ratio and D-dimer in patients versus controls.

Main Results:

  • Cirrhotic patients exhibited a hypercoagulable state (higher ETP ratio and D-dimer).
  • Significant differences in fibrinogen, ETP ratio, D-dimer, and platelet count were observed based on hemorrhagic score and ETP ratio thresholds.
  • Higher ETP ratio correlated with increased D-dimer and decreased fibrinogen/platelets.

Conclusions:

  • Liver cirrhosis is associated with a hypercoagulable state.
  • This state involves increased D-dimer and decreased fibrinogen/platelets, suggesting low-grade intravascular coagulation.
  • This condition predicts a high hemorrhagic risk in cirrhotic patients.
Abstract

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
27
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.4K
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
179
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
10.1K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
28
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
419